International Publication - Tigilanol Tiglate Canine Dose Characterisation Study

11 April 2019

The tigilanol tiglate canine dose characterisation study has been published as an original research article in the leading international journal, Frontiers in Veterinary Science. This external endorsement of the clinical trial results by the USA based manuscript review panel represents another important milestone progressing towards the commercialisation of our first pharmaceutical, tigilanol tiglate for canine mast cell tumours globally.

As quoted in the publication "This dose characterization study identified that tigilanol tiglate at a concentration of 1 mg/mL dosed at 0.5mL per cm3 of tumor volume (50% v/v tumor), is highly efficacious for the treatment of MCT in dogs. The drug was also demonstrated to be well tolerated and safe for the patient population treated, with adverse events being mild and of short duration. These results support further development of tigilanol tiglate for the treatment of MCT, and potentially other solid tumors, in dogs and underpins dosing regimen for future studies".

The international 11 site canine mast cell tumour pivotal efficacy trial is also now complete, with the results being submitted to the USA FDA-CVM and European EMA for review in Q4, 2018. To date, there are only a very small number of registered treatments for cancer in companion animals, providing a significant opportunity for tigilanol tiglate in this growing market.


Miller J et al. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. Frontiers in Veterinary Science, Volume 6, Article 106, April 2019